Fig. 4.
Avasimibe inhibited PCa growth and migration in vivo. a Tumour-bearing models were constructed by inoculating 2 × 106 PC-3 cells into the flanks of mice (n = 7). Seven days later, avasimibe (30 mg/kg) and PBS were injected intraperitoneally on alternate days for 7 weeks. We separated and weighed the tumour tissues; b volume of the tumours; c H&E staining and immunofluorescence staining of tumours to assess the expression of Ki67 and E2F-1; d pulmonary metastasis models were constructed by injecting 2 × 106 PC-3 cells (LV-NC GFP-expressing) into the tail vein of mice (n = 5). Avasimibe (30 mg/kg) and PBS were administered as described above for 7 weeks. e Fluorescence intensity of lung metastatic tumours was detected and statistically analysed. f H&E staining of the lungs. ***p < 0.001